Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 759 (miR-759)
- Target
- miR-759
- Molecular classification
- Non-coding RNA, MicroRNA (miRNA)
01
Overview
MicroRNA 759 (miR-759, MIR759) is a small, single-stranded, non-coding RNA classified as a microRNA that regulates gene expression post-transcriptionally. In humans, miR-759 has been implicated in the regulation of the coagulation system and vascular biology, particularly influencing susceptibility to chronic thromboembolic pulmonary hypertension by targeting the 3′ untranslated region of the fibrinogen-α gene (FGA). Like other microRNAs, miR-759 works via complementary base pairing to specific mRNA molecules, leading to translational repression or mRNA degradation, and thus modulates a variety of cellular processes, though its specific biological roles and therapeutic relevance remain incompletely characterized.
- Other names
- hsa-miR-759MIR759MIR759 (according to GeneCards)
02
Mechanism of action
Not directly applicable; if targeted, potential mechanisms of action would be antagomirs or miRNA inhibitors designed to sequester or degrade the microRNA, thus lifting repression on its target mRNAs. No such drugs are reported for miR-759 specifically.
03
Biological functions
Negative regulation of gene expression at the post-transcriptional levelInvolved in mRNA degradation or translational repression via binding to the 3' untranslated region (UTR) of target mRNAsPotential role in hemostasis and regulation of genetics relevant to proliferative vascular diseases according to miRNA class function
04
Disease associations
Pulmonary hypertension, particularly chronic thromboembolic pulmonary hypertension (CTEPH) via interactions with the 3' UTR of fibrinogen-α gene (FGA), affecting gene expression and possibly influencing disease susceptibilityMay have broader association in vascular or metabolic dysfunction as typical for many miRNAs
05
Safety considerations
No direct safety concerns reported, as miR-759 is not an established therapeutic targetGeneral therapeutic targeting of microRNAs poses potential risks of off-target effects due to miRNA's regulation of multiple genes
06
Biomarkers
No established biomarkers for patient selection or efficacy monitoring specific to miR-759Some literature suggests the presence or polymorphism in its target sites (such as the FGA 3′-UTR) may be associated with CTEPH susceptibility, but this is not broadly clinically used
Beyond the preview
Go deeper on MicroRNA 759 (miR-759).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MicroRNA 759 (miR-759).